Moderna (MRNA) Stock Forecast & Price Target

$39.08 +0.58 (+1.50%)

As of 12:31 PM Eastern

Moderna - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 23 Analyst Ratings

Sell
4

Hold
13

Buy
6

Based on 23 Wall Street analysts who have issued ratings for Moderna in the last 12 months, the stock has a consensus rating of "Hold." Out of the 23 analysts, 4 have given a sell rating, 13 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for MRNA.

Consensus Price Target

$75.58
93.41% Upside

According to the 23 analysts' twelve-month price targets for Moderna, the average price target is $75.58. The highest price target for MRNA is $179.00, while the lowest price target for MRNA is $27.00. The average price target represents a forecasted upside of 93.41% from the current price of $39.08.

Get the Latest News and Ratings for MRNA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Moderna and its competitors.

MRNA Analyst Ratings Over Time

Type	Current Forecast 1/24/24 to 1/23/25	1 Month Ago 12/25/23 to 12/24/24	3 Months Ago 10/26/23 to 10/25/24	1 Year Ago 1/24/23 to 1/24/24
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	4 Buy rating(s)	5 Buy rating(s)
Hold	13 Hold rating(s)	12 Hold rating(s)	14 Hold rating(s)	10 Hold rating(s)
Sell	4 Sell rating(s)	4 Sell rating(s)	2 Sell rating(s)	3 Sell rating(s)
Consensus Price Target	$75.58	$79.50	$94.65	$125.40
Forecasted Upside	93.41% Upside	97.42% Upside	78.28% Upside	24.03% Upside
Consensus Rating	Hold	Hold	Hold	Hold

MRNA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MRNA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Moderna Stock vs. The Competition

Type	Moderna	Medical Companies	S&P 500
Consensus Rating Score	2.13	2.82	2.52
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	96.31% Upside	25,553.87% Upside	11.77% Upside
News Sentiment Rating	Neutral News See Recent MRNA News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/16/2025	Leerink Partners 1 of 5 stars		Lower Target	Underweight ➝ Underweight	$31.00 ➝ $27.00	-19.99%
1/16/2025	Berenberg Bank 2 of 5 stars	H. Gillis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Hold ➝ Hold	$33.00 ➝ $42.00	+24.46%
1/15/2025	Morgan Stanley 3 of 5 stars	Matthew Harrison Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$70.00 ➝ $38.00	+8.57%
1/8/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$108.00 ➝ $96.00	+114.67%
12/18/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Hellweg Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
12/10/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Underperform	$41.00	-10.19%
11/26/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$59.00 ➝ $45.00	+3.85%
11/18/2024	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Y. Liu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
11/18/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$115.00 ➝ $69.00	+76.83%
11/18/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$58.00	+57.39%
Get the Latest News and Ratings for MRNA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Moderna and its competitors with MarketBeat's FREE daily newsletter.
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$40.00	+0.58%
11/8/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$125.00 ➝ $111.00	+134.08%
11/8/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
10/17/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Breen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$55.00	-4.28%
10/15/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$65.00 ➝ $55.00	-4.75%
9/19/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Issi Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$75.00 ➝ $75.00	+6.47%
9/16/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$178.00 ➝ $139.00	+101.19%
9/13/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$70.00 ➝ $60.00	-9.92%
9/13/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
8/7/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Sell ➝ Hold	$85.00 ➝ $80.00	-2.79%
6/27/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform
6/27/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	In-Line ➝ In-Line	$120.00 ➝ $120.00	-2.00%
5/3/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$91.00 ➝ $106.00	-15.20%
6/26/2023	51job Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Upgrade
4/25/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral
2/24/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Market Perform ➝ Underperform	$111.00 ➝ $93.00	-36.98%
1/25/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Market Perform	$130.00 ➝ $150.00	-23.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 12:31 PM ET.

Should I Buy Moderna Stock? MRNA Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, January 12, 2025. Please send any questions or comments about these Moderna pros and cons to contact@marketbeat.com.

Moderna
Bull Case

Here are some ways that investors could benefit from investing in Moderna, Inc.:

Recent earnings report showed a significant revenue increase to $1.90 billion, surpassing analyst expectations of $1.25 billion, indicating strong business performance.
Current stock price is $43.66, reflecting a 6.2% increase in trading, which may suggest positive market sentiment towards the company.
Analysts have a consensus rating of "Hold" with a price target averaging $84.00, indicating potential for price appreciation based on future performance.
Institutional investors own 75.33% of the company's stock, suggesting strong confidence from large financial entities in Moderna's future prospects.
Moderna's innovative approach in messenger RNA therapeutics positions it well in the biotechnology sector, potentially leading to breakthroughs in various diseases.

Moderna
Bear Case

Investors should be bearish about investing in Moderna, Inc. for these reasons:

Moderna reported a negative net margin of 43.77%, indicating that the company is currently spending more than it earns, which could be a red flag for profitability.
The stock has experienced significant volatility, with a 1-year high of $170.47 and a low of $35.80, suggesting uncertainty in its market performance.
Recent insider selling, including the CFO selling shares, may indicate a lack of confidence in the company's short-term prospects.
Analysts have mixed ratings, with three giving a sell rating, which could reflect concerns about the company's future growth potential.
The company has a P/E ratio of -7.19, which means it is currently not generating profits relative to its stock price, making it a riskier investment.

MRNA Forecast - Frequently Asked Questions

: According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Moderna is $75.58, with a high forecast of $179.00 and a low forecast of $27.00.
: 23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Moderna in the last year. There are currently 4 sell ratings, 13 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRNA, but not buy additional shares or sell existing shares.
: According to analysts, Moderna's stock has a predicted upside of 93.41% based on their 12-month stock forecasts.
: Over the previous 90 days, Moderna's stock had 2 upgrades and 1 downgrade by analysts.
: Moderna has been rated by research analysts at Argus, Bank of America, Barclays, Berenberg Bank, Hsbc Global Res, HSBC, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Needham & Company LLC, Piper Sandler, UBS Group, and Wolfe Research in the past 90 days.
: Analysts like Moderna less than other "medical" companies. The consensus rating for Moderna is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MRNA compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NASDAQ:MRNA) was last updated on 1/23/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Moderna (MRNA) Stock Forecast & Price Target